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Abstract
Cholestatic liver diseases (CLDs) encompass a variety of disorders of abnormal bile formation 
and/or flow. CLDs often lead to progressive hepatic insult and injury and following the 
development of cirrhosis and associated complications. Many such complications are clinically 
silent until they manifest with severe sequelae, including but not limited to life-altering symptoms, 
metabolic disturbances, cirrhosis, and hepatobiliary diseases as well as other malignancies. 
Primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC) are the most common 
CLDs, and both relate to mutual as well as unique complications. This review provides an 
overview of PSC and PBC, with a focus on preventive measures aimed to reduce the incidence and 
severity of disease-related complications.
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1. Introduction
“Cholestasis” is a compound expression from the Greek word meaning “standing still of 
bile”. Liver disease that occurs due to or characterized by cholestasis is often referred to as 
cholestatic liver disease (CLD). CLD includes a wide variety of disorders, including genetic, 
congenital, immunological, infectious, and idiopathic. The site of impaired bile formation or 
flow through the biliary tract in CLDs can be at essentially any level, be it the hepatic 
canaliculi, ductules, or large ducts, and as such, manifestations and management may vary 
accordingly. Primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC) 
embody the most impactful CLDs, both being associated with significant morbidity and 
mortality worldwide. During the past decade, there have been considerable developments in 
the understanding and clinical care of PSC and PBC as well as their associated 
complications, including cirrhosis, liver failure, malignancies, bone disease, and nutritional 
deficiencies. This review focuses on the established and emerging preventive measures 
aimed at mitigating morbidity due to the symptoms, complications, and diseases associated 
with PSC and PBC.
2. Overview of PSC and PBC
2.1. Pathogenesis
PSC is an idiopathic, chronic, progressive CLD associated with inflammation, fibrosis, and 
stricture formation involving intrahepatic and/or extrahepatic biliary ducts.1 Several 
genotypic and human leukocyte antigen (HLA) haplotype associations have been detected 
with PSC.1–6 One proposed hypothesis is that PSC may develop following exposure of a 
pre-disposed individual to (as yet uncertain) exogenous factors, including, but not limited to, 
perturbations in the enteric microbiome.7
In comparison, PBC, formerly known as “primary biliary cirrhosis”, is considered to be an 
autoimmune disease caused by environmental insults in genetically predisposed individuals 
(Table 1).8 Epidemiological studies have suggested various potential etiologic insults and 
associations, including exposure to nail polish, xenobiotics, and smoking, among others.9–11
2.2. Clinical epidemiology
The incidence and prevalence of PSC vary with geographic location, and in many regions of 
the world, remain unknown. In the United States, the estimated incidence and prevalence of 
PSC range from 0.5 to 1.5 and 5–16 per 100,000 individuals, respectively.1 Approximately 
5% of patients with inflammatory bowel disease (IBD) have PSC, whereas nearly 75% of 
patients with PSC have IBD. In Far Eastern populations, a smaller proportion of patients 
with PSC (closer to 20%) have IBD, the underlying reasons for which remain unclear. PSC 
has an approximately 2:1 male predominance pattern and is most commonly diagnosed 
around 30–40 years of age, though presentation may be much earlier or later in life.1
Compared to PSC, PBC affects women more commonly, with a 9:1 female-to-male ratio 
(Table 1). PBC has a higher global incidence and prevalence, with an age-adjusted incidence 
of 2.7 and prevalence of 40 per 100,000 person-years, respectively.12–14 A large proportion 
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of patients with PBC are asymptomatic and with early stage disease when diagnosed;15 
however, African American and Latino populations have been reported to have more severe 
liver disease upon initial diagnosis, the reason for which are not well understood.16
2.3. Signs and symptoms
Approximately 50% of patients who are diagnosed with PSC are asymptomatic at the time 
of diagnosis. In these patients, the diagnosis is often made following the evaluation of 
abnormal serum liver tests in patients with IBD or incidentally noted abnormal serum liver 
tests in individuals undergoing routine or health insurance-related screening. Among those 
who do have symptoms, fatigue and pruritus tend to be the most common and complicated. 
Fatigue is non-specific, as it can be seen in other CLDs and advanced liver disease in 
general, and its etiology in CLDs is unclear. Pruritus is a presenting symptom in 
approximately one-third of patients with PSC.17 It is exacerbated by heat, pregnancy, wool 
exposure, and can be worse at night. It has been proposed that increased levels of circulating 
bile salts, opioidergic molecules, and other metabolites may cause pruritus in CLD, though 
these have been only variably replicated.18,19 Though PSC is a chronic, usually slowly 
progressive disease that can remain asymptomatic for a prolonged period of time, some 
patients follow an aggressive, highly symptomatic disease course and/or present with 
jaundice, recurrent acute cholangitis, and already advanced liver disease, all of which may 
portend a worse prognosis.
Patients with PBC tend to invariably develop symptoms within a median of 2–4.2 years of 
diagnosis.20,21 Having early symptomatic disease appears to be associated with a shorter 
median survival;20,21 indeed, one study for example showed a median survival of 7.5 years 
for symptomatic patients as compared to 16 years for asymptomatic patients.22 PBC shares 
generally similar symptoms with PSC, including pruritus and fatigue. Fatigue is the most 
common symptom, affecting approximately 78% of patients with PBC and is associated 
with autonomic neuropathy, hypothyroidism, and overall decreased survival.23–26 Pruritus is 
a more specific symptom in PBC (and CLDs in general), affecting approximately 30–70% of 
patients. Several etiologies have been proposed to account for this symptom, including 
increased opioidergic neurotransmission and circulating bile salts, similar to PSC.27–29 
Proposed therapies for pruritus in PBC as well as PSC are discussed in a subsequent section.
In addition to the signs and symptoms associated with bile acid stasis, CLDs accompany 
with immunological disorders (and their respective signs and symptoms), including thyroid 
disease, cutaneous calcinosis, Raynaud’s phenomenon, and sicca syndrome.
2.4. Diagnostic approach
The diagnosis of PSC is based on a chronically cholestatic biochemical profile, typically 
elevated serum alkaline phosphatase (ALP), along with cholangiographic evidence of 
multifocal biliary tree strictures.30 Liver biopsy may be useful to rule out disease mimics or 
overlap syndrome with autoimmune hepatitis, rule in small duct PSC (a variant phenotype), 
or when the diagnosis of PSC is in question based on atypical serologic, cholangiographic, 
or other clinical findings.31 Periductal “onion skin” fibrosis is considered a pathognomic 
microscopic characteristic of PSC but is seldom found in biopsy specimens; the more typical 
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histopathological findings include paucicellular, nonsuppurative cholangitis and ductular 
reaction with varying degrees of biliary fibrosis (on which Ludwig staging is based).32 
Elevated serum IgG4 levels are present in 10% of patients with PSC and are associated with 
rapidly progressive disease; some of these patients may in fact have IgG4-associated 
sclerosing cholangitis, which is frequently responsive to corticosteroid therapy.33–36 Hence, 
it is recommended that all patients with PSC be tested at least once for IgG4 levels. With 
regard to cholangiography, magnetic resonance cholangiography (MRCP) has largely 
supplanted endoscopic retrograde cholangiopancreatography (ERCP) for diagnostic 
purposes, with the latter being reserved for cases requiring therapeutic intervention or 
acquisition of specimens.37
The diagnosis of PBC is made on the presence of ALP levels 1.5 times higher than the upper 
limit of normal for at least six months, positive antimitochondrial antibody (AMA), and 
absence of extrahepatic biliary obstruction on imaging studies.38–40 AMA is 90–95% 
sensitive and specific for PBC.41,42 As with PSC, liver biopsy is not required for diagnosis 
but may be advisable in cases with diagnostic uncertainty (e.g. negative AMA) and to 
exclude other and/or concomitant diseases. Typical histologic findings include chronic, non-
suppurative, lymphocytic cholangitis involving septal and interlobular ducts with varying 
degrees of biliary fibrosis.
2.5. Disease treatment
To date, there is no approved pharmacologic therapy for PSC. Ursodeoxycholic acid 
(UDCA) has been the most studied drug for treatment of PSC but its therapeutic impact 
remains controversial. A large Scandinavian trial reported that a dose of 17–23 mg/kg/day 
brought clinical and biochemical improvement in patients but the results did not attain 
statistical significance and hence did not improve the survival.43–45 High dose (28–30 
mg/kg/day) UDCA have also been associated with higher rates of death, need for liver 
transplantation (LT), and colorectal carcinoma.46 Thus the general use of UDCA for patients 
with PSC is not recommended by American Association for the Study of Liver Diseases 
(AASLD). Obeticholic acid (OCA) is under trial to investigate the role in reversing fibrosis 
and preventing cirrhosis in PSC.47 Several other treatments have been tested, including 
azathioprine, budesonide, methotrexate, mycophenolate mofetil, pentoxifylline, tacrolimus, 
nicotine, and pirfenidone, without proven benefit.48–61 Numerous agents, including but not 
limited to oral vancomycin and curcumin,62,63 are currently under various phases of 
investigation for treatment of PSC, targeting a variety of different signaling pathways.64 
With regard to non-pharmacologic treatment, the current therapeutic mainstays are 
endoscopic (discussed in detail in a recent review and summarized in a subsequent section 
herein) and surgical.65 Surgical therapies include resection and LT. Resection is primarily 
performed in patients with pre-cirrhotic, focal disease (e.g. early-stage distal biliary 
cholangiocarcinoma (CCA)), while LT is recommended in those who have advanced 
cirrhosis or conditions meeting criteria for exception status, e.g. recurrent acute cholangitis 
with ≥2 episodes of bacteremia or a one-time episode of sepsis, hilar CCA meeting specific 
criteria, and/or intractable pruritus.66 LT in PSC has been shown to significantly improve 
survival, with a 5-years survival rate of approximately 80%; however, the risk of recurrence 
of PSC post-LT has been reported to be 34–67%.67
Malik et al. Page 4
Liver Res. Author manuscript; available in PMC 2020 February 10.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Unlike in PSC, UDCA is the primary Food and Drug Administration (FDA) approved 
therapy for PBC (Table 1). UDCA at a dose of 13–15 mg/kg/day has been shown to reduce 
the risk of developing varices or requiring LT, improve serum liver biochemistries, and 
prolong survival in patients with PBC, particularly when started early in the disease course.
68–70
 Improvements in liver biochemistries can occur within weeks of starting UDCA, with 
90% of the improvement seen within 6–9 months. UCDA has not been shown to 
significantly many of the symptoms associated with PBC, including fatigue and pruritus, or 
complications such as bone or thyroid disease. The use of UCDA has minimal side effects 
including non-progressive weight gain in the first year of therapy, dyspepsia, and hair loss.71 
Recently, OCA, a farnesoid X receptor agonist, was approved by the FDA for treatment of 
PBC.72–79 OCA can be used in combination with UDCA or as monotherapy in patients who 
are unable to tolerate UDCA and appears to be effective in reducing ALP levels. However, it 
has not yet been shown to improve survival or disease-related symptoms and can cause 
pruritus and headache as a side effect.80–82 Similar to PSC, LT in PBC has shown excellent 
1-year and 5-years survival rates of 90% and 85%, respectively.83 A few studies have 
reported post-LT PBC recurrence rates of 8–18% and 22–30% at 5 and 10 years, 
respectively.84
2.6. Symptom management
2.6.1. Fatigue—To date, no known effective therapy exists for fatigue related to CLDs. 
The general therapeutic approach involves ruling out secondary causes (e.g. depression, 
hypothyroidism) and providing supportive care. Trials of vancomycin, metronidazole, and 
rifaximin have shown promising effects on fatigue in patients with PSC, but further 
investigation is needed before these agents can be routinely recommended for this 
indication.85,86 Modafinil at doses of 100–200 mg/day may have some improvement in 
fatigue domain scores as an effective therapy in treating daytime somnolence associated with 
shift work but is not routinely recommended.87 New-onset pruritus should be further 
evaluated to rule out the formation of a dominant bile duct stricture (DS). Once a DS has 
been ruled out, symptomatic control with use of cholestyramine, sertraline, rifampicin, 
and/or naltrexone in a stepwise manner is recommended.88 Hydroxyzine, gabapentin, 
ondansetron, antibiotics, extracorporeal albumin dialysis and plasmapheresis, may also be 
considered.89–92
2.6.2. Pruritus—Unfortunately, UDCA does not relieve pruritus in a large proportion of 
patients; therefore, other interventions to manage pruritus are often needed. Bile acid 
sequestrants, such as cholestyramine, have been associated with improvement in pruritus 
symptoms in patients with PBC.93,94 The recommended dose of cholestyramine is 4 g per 
dose, with a maximum of 16 g per day, administered 2–4 h before or after UDCA. In 
patients who are refractory to bile acid sequestrants, other recommended therapies include 
rifampicin 150–300 mg twice daily, oral opiate antagonists such as naltrexone 50 mg daily, 
and sertraline 75–100 mg daily.95
2.6.3. Sicca symptoms—General measures are used to improve eye care and oral 
health in patients with sicca symptoms. Treatment of dry eyes, includes humidification of 
the household environment, artificial tears such as hydroxypropyl methylcellulose and 
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carboxymethylcellulose, or cyclosporine ophthalmic emulsion as a second line therapy if not 
responsive to artificial tears.95 Oral health includes regular visits to the dentist, mouth 
rinsing with water, use of fluoride-containing toothpaste, daily flossing, and sugar 
avoidance. Saliva substitutions or cholinergic agents such as pilocarpine and cevimeline can 
also be considered and may be very effective in some patients.95 Dry skin could be treated 
with moisturizing creams and/or ointments.
3. General preventive measures
Patients are often asymptomatic at the time of diagnosis, which may give a false impression 
of lack of significant disease. This, coupled with the fact that approved medical therapy is 
lacking PSC and that therapy for PBC is ineffective in some patients, renders preventative 
strategies particularly important for patients with these disorders. Preventive measures to 
prevent complications from and slow down the progression of the underlying disease process 
are discussed hereinafter.
3.1. Alcohol consumption
More than four drinks (48 g of ethanol) per day is associated with an increased risk of 
cirrhosis, hepatocellular carcinoma (HCC), and premature death.96 Acites, hepatic 
encephalopathy and variceal bleeding risk were reported to be approximately 50% after 5 
years.97 Alcohol is a direct toxin to hepatocytes and thus causes hepatitis and fatty 
infiltration.98 Ethanol can also induce hepatic cholestasis, the mechanism of which is not 
well understood but may be related to compression of intrahepatic biliary radicals or 
derangement of basolateral uptake and bile acid transport. Hence, it may mimic a CLD.99 
There is no known safe alcohol consumption level in patients with underlying liver disease. 
One study reported that alcohol plays both a synergistic and additive roles in cirrhosis 
development in patients with other hepatic diseases (e.g. hepatitis C).98 Alcohol has also 
been reported to be a risk factor for CCA in patients with PSC.100 One study on untreated 
patients with PBC demonstrated that moderate amount of alcohol consumption is an 
independent predictor of late stage PBC disease.101 Hence, it is recommended to abstain 
completely from alcohol consumption.
3.2. Immunizations
Acute hepatitis due to superinfections with hepatitis A and B viruses can be more severe in 
the presence of chronic liver disease.102–105 It is imperative that all patients with chronic 
liver disease due to any cause to be tested for hepatitis A and B infections. If no immunity is 
found, vaccinations should be administered (Table 2).106–108 Several studies in patients with 
chronic liver disease have shown that the seroconversion after hepatitis A and B vaccinations 
was achieved in 94% and 100% of patients respectively.109 One time pneumococcal 
vaccination is also recommended in patients with cirrhosis to prevent spontaneous bacterial 
peritonitis (SBP) due to streptococcal pneumonia infection before the age of 65, which 
should then be administered at 5–10 years intervals at or after the age of 65.110 Yearly 
influenza vaccination should also be administered given the association of influenza with 
increased mortality in individuals with cirrhosis.111
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3.3. Toxins (medications and vitamins)
Numerous common medications, vitamins, and over the counter supplements are known to 
cause liver injury, and may be particularly unsafe in patients with underlying chronic liver 
disease. Careful review of medications should be done during each patient encounter, and 
patients should be informed about possible adverse hepatic side effects. If a hepatotoxic 
medication is identified, efforts should be made to find alternative treatment options; if no 
other options are available, a plan for regular monitoring for liver signs and symptoms of 
toxicity should be devised. If evidence of toxicity is detected, the offending agent should be 
promptly discontinued.112 Medications including non-steroidal anti-inflammatory drugs 
(NSAIDs), aminoglycosides, and benzodiazepines should be avoided in patients with 
cirrhosis. NSAIDs are commonly associated with idiosyncratic liver toxicity, greater 
bleeding risk, and renal injury in patients with cirrhosis.113 Acetaminophen at a daily dosage 
that does not exceed 2 g is safer than NSAIDs in individuals with chronic liver disease, as it 
has dose-dependent predictable toxicity to the liver and is not nephrotoxic and does not 
increase the risk of gastrointestinal (GI) bleeding. Similarly, vitamin A is hepatotoxic in 
large doses, i.e. 100,000 IU per day, but is safe in regular doses.114 Iron overload can be 
hepatotoxic to patients with the chronic liver disease since it can lead to free radical injury to 
hepatocytes.115 Iron supplements should typically not be used, as patients with liver disease 
already often have excessive iron stores in the liver.116 Estrogen therapy should be avoided 
in patients with CLD as it can promote cholestasis and exacerbate pruritus.
3.4. Dietary fat
Fatty infiltration in the liver, which often occurs in the presence of predisposing metabolic 
conditions including diabetes, obesity, and elevated triglyceride levels, can further promote 
progression to chronic liver disease and cirrhosis through hepatic inflammation, and 
subsequent fibrosis and necrosis.117 Hence a low-fat diet and a physician-supervised 
exercise plan are recommended for gradual weight reduction in chronic liver disease 
patients. Patients with PBC also often are diagnosed with hyperlipidemia, including elevated 
high-density lipoproteins cholesterol and lipoprotein X accumulation. However, these 
elevations do not confer any increased mortality risk due to atherosclerosis.118–121 
Therefore, no specific therapy is required to reduce cholesterol levels, though UDCA is 
often used to lower low-density lipoproteins (LDL) cholesterol levels.
3.5. Raw oysters/shellfish
Patients with CLD should avoid consuming raw oysters. Filter feeders like oysters harbor a 
fatal bacterium named Vibrio vulnificus, which causes septicemia in patients with liver 
disease. It has the highest seafood consumption-associated mortality rates in the United 
States. It is extremely important to keep a high index of suspicion in a patient with chronic 
liver disease and recognize that doxycycline is the life-saving medication in such 
circumstances. Modes of transmission include the oral route and through skin via open 
wounds. Patients may present with acute gastroenteritis, septic shock, and blistering on the 
skin regardless of the mode of transmission.122 Hence, it is essential to educate patients to 
avoid consumption of raw seafood and exposure of open wounds to marine water.
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3.6. Coffee consumption
Coffee is an important source of antioxidants due to its widespread use and has been 
associated with a protective effect in heart disease, stroke, diabetes mellitus type 2 and 
Parkinson disease.123–126 Caffeine has also been proposed to have both antifibrotic (inhibits 
hepatic stellate cells) and anti-inflammatory effects in the liver.127 Two cups of coffee daily 
in patients with chronic liver disease is associated with decreased fibrosis/cirrhosis, lower 
risk of hepatocellular carcinoma, and decreased mortality.127 In patients with PSC, one 
study also showed delayed progression to end stage liver disease and increased survival post-
LT in patients who consumed coffee.128 Therefore, daily moderate coffee consumption can 
be considered in patients with PSC due to its potential beneficial effects.
3.7. Screening family members
There is an increased risk of PBC reported among first-degree relatives with positive family 
history.129 Screening can be initiated by testing ALP levels, which if found elevated, can 
further be investigated with AMA testing.
4. Cirrhosis, portal hypertension, and their sequelae
Cirrhosis is a later-stage complication in CLD. A majority of patients with PSC will go on to 
develop progressive fibrosis, portal hypertension, and end-stage liver disease (ESLD), which 
occurs approximately 20 years from the time of initial PSC diagnosis.130 General 
preventative measures for cirrhosis should also be implemented, as briefly reviewed below.
It is recommended that a screening upper endoscopy be performed in all newly diagnosed 
cirrhosis cases to rule out gastroesophageal varices.131 Patients with large esophageal 
varices should receive treatment, be it banding or non-selective beta-blocker therapy. In 
patients with small varices with a high risk of bleeding (e.g. high-risk endoscopic stigmata), 
prophylactic non-selective beta-blockers are recommended.
Patients should be administered antibiotics for SBP prophylaxis if they have cirrhosis and GI 
bleeding, a prior history of SBP,132 or an ascitic fluid total protein concentration less than 
1.5 g/dL with either renal dysfunction or liver failure and variceal hemorrhage.133 
Norfloxacin 400 mg daily is effective in SBP prophylaxis in patients with a history of SBP 
or low protein ascites while norfloxacin 400 mg twice daily for seven days is effective in 
variceal bleeding patients.134–136
Hepatic encephalopathy (HE) is present in up to 80% of patients with decompensated 
cirrhosis and can present with a wide spectrum of severity, from mild cognitive impairment 
(e.g. difficulty remembering and mental haziness) to a comatose state.137 Rifaximin, a non-
selective, locally-acting antibiotic, used along with lactulose or as monotherapy is effective 
in the treatment of HE.138,139
Finally, screening for HCC should be implemented with either an abdominal ultrasound or 
cross-sectional imaging with or without alpha-fetoprotein levels at 6–12 months intervals.140
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5. Prevention and management of associated disorders and disease
5.1. Cancer surveillance
Table 3 summarizes preventative measures and management of complications of PBC and 
PSC. Colorectal dysplasia and cancer in patients with PSC-IBD occurs at a rate of 4–5 times 
that seen in patients with IBD without PSC, which itself is several-fold higher than in the 
general population.141 The mechanism underlying this observation is unknown but is 
proposed to be due to the carcinogenic effects of an abnormal bile acid pool.142 Individuals 
with PSC are also at a significantly higher risk of developing CCA, with a 10-years risk of 
approximately 8%, a rate that is several hundred times higher than that in the general 
population.143 Therefore, patients with PSC should be advised to avoid smoking and alcohol 
abuse. Very rarely the occurrence of hepatocellular and pancreatic cancers have been 
reported.144–147 Given the higher rates of CCA in this population, it is recommended that 
screening be performed with abdominal ultrasound or magnetic resonance imaging (MRI) 
and carbohydrate antigen (CA)19–9 levels every 6–12 months in all adults patients with 
PSC.148,149 Patients with PSC also have increased risk of developing gallbladder cancer, due 
to the higher risk of forming gallstones.150 Those with gallbladder polyps ≥8 mm in size 
should undergo cholecystectomy given the high likelihood of malignant transformation,151 
and those with polyps <8 mm should annual surveillance with ultrasound.152
Patients with PBC should be similarly screened for malignancy. Once PBC progresses to 
advanced fibrosis or cirrhosis, patients should be screened every 6 months for HCC with 
cross-sectional imaging with or without alpha fetoprotein at six-months intervals.153
5.2. IBD in PSC
Approximately 80–90% of patients with PSC have IBD.149 IBD in patients with PSC can 
often be asymptomatic,154 however, right-sided colitis with relative rectal sparing, backwash 
ileitis, pouchitis after ileoanal anastomosis, portal hypertension (HTN) with stomal/
peristomal varices are commonly seen in IBD with PSC.1,30 It is therefore recommended to 
do chromoendoscopic annual surveillance colonoscopy in patients with PSC with colitis 
starting from the time of diagnosis. Also, a full colonoscopy with four-quadrant biopsies 
every 10 cm should be obtained at the time of PSC diagnosis regardless of symptoms or 
presence of normal mucosa.30 IBD is not associated with PBC.
5.3. Autoimmune hepatitis (AIH) overlap syndrome and IgG4-associated sclerosing 
cholangitis
AIH can co-exist/overlap with PSC in about 10% of the population.1,30 This overlap 
syndrome of AIH-PSC usually effects younger individuals less than 25 years of age, and in 
one study AIH was followed by PSC development in children.155 Therefore it is reasonable 
to evaluate younger patients with MRCP if they develop AIH or have aminotransferase 
levels >2x the upper limit of normal.1 Similarly, AIH can overlap with PBC, however there 
is no formal definition of the overlap syndrome. Overlap syndrome should be considered 
when patients have clinical features of both AMA-positive PBC and AIH. The natural 
history of patients with AIH-PBC overlap syndrome is variable, though these patients often 
exhibit significantly higher rates of portal hypertension, portal hypertension-related GI 
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bleeding (e.g. from esophageal varices), ascites, and death or need for LTcompared to those 
with PBC or AIH alone.156 Management for overlap syndrome should involve the use of 
UDCA with or without other immunosuppressive agents, though there is minimal evidence 
regarding the optimal therapy and timing of treatment.157
IgG4-associated sclerosing cholangitis, an autoimmune disease leading to biliary strictures 
and pancreatic duct strictures, can often mimic PSC. It can present similarly with a 
cholestatic pattern of liver enzyme elevation, however it usually associated with very high 
serum IgG4 levels (>140 mg/dl), positive IgG4-staining plasma cells, and 
lymphoplasmacytic infiltrates on liver biopsy.1,30 In contrast to patients with PSC, these 
patients are less likely to have concurrent IBD and generally have a better response to 
steroids and other immunosuppressive agents.
5.4. Dominant stricture in PSC
A dominant stricture is defined as a stenosis of <1.5 mm in the common bile duct (CBD) 
and <1.0 mm in the hepatic ducts (HD). Dominant strictures are the initial presentation of 
PSC in 45% cases, and almost 50% of the patients can develop dominant strictures as the 
disease progresses.158,159 PSC causes biliary obstruction at all levels of the biliary tree, but 
the strictures in major ducts may be amenable to ERCP. ERCP with balloon dilation and/or 
stent placement provides symptomatic relief from pruritus, prevents complications including 
cholangitis,160–164 allows for earlier diagnosis of CCA,165,166 and improves overall survival.
167–169
 It is recommended to give prophylactic antibiotic therapy before ERCP for dominant 
strictures due to biliary bacterial colonization and a higher risk of post-ERCP cholangitis.170 
ERCP with or without balloon dilatation and stent placement is the first line therapy for the 
strictures but if the patient has altered anatomy (due to Rouxen-Y or gastric bypass) that can 
prevent successful ERCP, then percutaneous cholangiography is the next treatment option.
171–173
5.5. Nutritional deficiencies and steatorrhea
Reduced bile flow from stricturing disease in PSC also leads to fat-soluble vitamin 
deficiencies and fat malabsorption. One study reported vitamins A, D and E deficiencies in 
82%, 57% and 43% of patients with PSC, respectively.174 Hence patients with PSC who 
have advanced liver disease should be screened for fat-soluble vitamin deficiency, and the 
same applies to patients with PBC.175 Oral supplementation is sufficient in most cases. 
Importantly, in patients who have steatorrhea, it is essential to rule out other (potentially 
comorbid) disorders, including sprue and pancreatic exocrine insufficiency, which may 
themselves cause fat-soluble vitamin deficiency, in select instances, replacement of long-
chain triglycerides with medium chain triglycerides may be needed. By contrast, water 
soluble vitamin deficiencies are uncommon is PSC and PBC.176
5.6. Osteodystrophy
Hepatic osteodystrophy develops due to increased bone resorption and decreased bone 
formation, and occurs in 12–50% of patients with PSC.177–180 Smoking and alcohol 
cessation, gentle weight bearing exercise regimen, and oral vitamin D and calcium 
supplements are recommended for osteopenia and osteoporosis in PSC. Bisphosphonate 
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therapy should be considered for individuals with osteoporosis.181,182 Once diagnosed with 
PSC, surveillance (e.g. with dual-energy X-ray absorptiometry (DEXA)) is recommended, 
with the frequency of surveillance depending on other clinical risk factors for bone loss.183
One-third of patients with PBC develop osteoporosis.184,185 Unlike in PSC, in bone 
resorption is low in patients with PBC.186,187 Hence the risk of bone fracture is low, and 
vitamin D levels are normal except in jaundiced patients with advanced liver disease.188–190 
Therefore, bone mineral density (BMD) examination is recommended every 2–4 yearly 
depending on baseline BMD and disease severity. If there is evidence of osteodystrophy 
and/or low vitamin D levels, daily calcium (1500 IU/day) and vitamin D supplementation 
(1000 IU/day) can also be given in the absence of any contraindication.
5.7. Hypothyroidism
PBC is associated with hypothyroidism, and almost 10–22% of patients with PBC have a 
low functioning thyroid.191 Thus, thyroid function should be tested every year in patients 
with PBC. Thyroid dysfunction is less common in PSC but should be investigated if 
symptoms compatible with hypothyroidism (e.g. fatigue) are present.
5.8. Screening for celiac disease
Both PSC and PBC have been shown to be associated with celiac disease.192,193 Celiac 
disease superimposed on CLD can worsen malabsorption, weight loss, fat soluble vitamin 
deficiency, and osteoporosis. It is recommended to screen for Celiac disease in patients with 
PBC, and vice versa, to guide management for potential comorbid conditions.194
6. Other CLDs
While PSC and PBC are the most common CLDs, there are several others that occur in a 
variety of clinical settings and merit mention. For example, intrahepatic cholestasis of 
pregnancy (ICP) is characterized by generalized pruritus and elevations in serum bilirubin in 
the late second and/or third trimester and is the most common liver disease in pregnancy.195 
Pruritus in ICP may precede laboratory abnormalities, which also can include elevations in 
serum aminotransferases (usually to less than two times the upper limit of normal), 
elevations in ALP (up to four times the upper limit of normal), and mild to modest 
elevations in gamma-glutamyl transferase (GGT).196 The reported incidence of ICP varies 
widely, though in the United States, it ranges from 0.3 to 5.6%. Maternal bile acids can cross 
the placenta and accumulate in the amniotic fluid, increasing the risk of intrauterine demise, 
meconium-stained amniotic fluid, preterm delivery, and neonatal respiratory distress 
syndrome.197 UDCA is the preferred treatment.198 Another, more rare, cause of intrahepatic 
cholestasis is progressive familial intrahepatic cholestasis (PFIC). PFIC refers to a 
heterogeneous group of disorders characterized by a various of genetic mutations leading to 
defective secretion of bile acids or other components of bile. These disorders generally 
present during infancy or childhood and can lead to progressive liver failure, though some 
may have later presentation and a more indolent course. Initial therapy involves UDCA, 
though LT may be needed (and is curative).199 Lastly, benign recurrent intrahepatic 
cholestasis (BRIC) describes an inherited form of CLD characterized by intermittent 
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episodes of cholestasis.200 Patients can present from infancy to late adulthood with attacks 
of conjugated hyperbilirubinemia, anorexia, pruritus, and weight loss. Episodes last for 
weeks to months and then completely resolve. There is no curative treatment for BRIC, and 
LT is generally not indicated given the episodic, benign, and non-progressive nature of the 
disease.200 Further information regarding these and other CLDs not specifically addressed in 
this article can be found in other recent works.201–204
7. Conclusion
In conclusion, CLDs comprise a wide variety of disorders characterized by impaired bile 
formation or flow through the biliary tract. At present, there are limited therapeutic options 
to alter the course of the disease in patients with CLD, particularly PSC. Early diagnosis, 
treatment of symptoms, and surveillance for early detection and treatment of complications 
can help to reduce mortality and morbidity in both PSC and PBC, the two major CLDs. 
Avoidance of toxin exposure (alcohol, hepatotoxic medications) and other preventative 
measures including viral hepatitis vaccination and a healthy, low-fat diet may prevent 
additional hepatic injury and accelerated progression to advanced fibrosis or cirrhosis. 
General care should also involve management of fatigue and pruritus-related symptoms. 
Finally, management of cirrhosis-related complications, early referral for LT, and judicious 
hepatobiliary and colorectal cancer (CRC) surveillance can help to improve quality of life 
and survival.
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Table 2
General preventative measures for cholestatic liver disease.
General preventative measures for cholestatic liver disease
(i) Avoid hepatotoxins (alcohol, medications including NSAIDs, herbalsupplements)
(ii) Administer hepatitis A and B vaccinations
(iii) Administer one-time pneumovax if < 65 years old, and once >65 years old, revaccinate every 5–10 years
(iv) Yearly influenza vaccination
(v) Low-fat diet
Abbreviation: NSAIDs, non-steroidal anti-inflammatory drugs.
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